{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"2.410","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"588,835,343","primaryexch":"香港交易所","ric":"0950.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.1581,"inline_upper_strike_price":"","sedol":"BQZF1T7","am":"8.61","iv":"","ew_strike":"","as":"2.310","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"2.300","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"1.120","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"李小芳","underlying_ric":"0950.HK","hi52":"2.700","issuer_name":"李氏大藥廠控股有限公司","h_share_flag":false,"ew_sub_per_from":"","div_yield":"2.04","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"2.280","mkt_cap":"1.35","f_aum_hkd":null,"ew_sub_per_to":"","ls":"2.300","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"0.000","aum":"","issued_shares_class_B":null,"vo":"3.68","secondary_listing_flag":false,"listing_date":"2002年7月15日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"李氏大藥廠控股有限公司","nm_s":"李氏大藥廠","sym":"950","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"李氏大藥廠控股有限公司是一家主要從事藥品開發、製造、市場推廣及銷售業務的投資控股公司。該公司通過兩個分部運營業務。引進產品分部買賣引進的產品。其引進產品包括可益能註射液、菲普利口服溶液等。專利產品分部製造及銷售自行研發的產品。其研發產品包括銳思力藥片、ADASUVE吸入粉霧劑等。該公司藥品覆蓋心血管及傳染疾病、皮膚醫學、腫瘤學、婦科學及眼科學等領域。該公司主要在中國大陸、香港、臺灣開展業務。","op":"2.290","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"14/05/2010","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港新界沙田<br/>香港科學園第三期<br/>科技大道東<br/>20E大樓1樓","pc":"0.00","days_to_expiry":null,"underlying_code":null,"pe":"14.55","eps_ccy":"HKD","hdr":false,"launch_date":"","hc":"2.300","isin":"KYG5438W1116","moneyness":""}},"qid":"1759074399261"}
